United States: US FDA Issues Warning Letter To Stem Cell Treatment Centers

The US Food and Drug Administration ("FDA") has sent a Warning Letter covering three physician-operated stem cell treatment centers in California, Florida and New York asserting that the centers have unlawfully recovered and processed adipose (fat) tissue to perform stem cell therapy and deviated from current good manufacturing practice ("CGMP") and current good tissue practice ("CGTP") in doing so. The issuance of a Warning Letter in these circumstances is significant because it may signal a departure from FDA's past practice of less strict regulatory enforcement against practitioners of stem cell therapies.

The procedure at issue is relatively common. The physician uses a needle to remove adipose tissue from the patient, isolates the stromal vascular fraction ("SVF") of the tissue and implants the SVF autologously, meaning back into the same patient. One of the most common therapies of this type is a relatively simple office procedure in orthopedic and rehabilitation medicine; the physician obtains SVF from the patient and injects it back into a surgical or arthritic joint, in an effort to promote the repair and replacement of diseased cartilage.

In this particular Warning Letter, FDA indicates that the treatment centers were obtaining and using autologous SVF to perform intravenous ("IV") or intrathecal (spinal) injections, or for nasal or oral nebulization. FDA notes that the treatment centers were using these procedures to treat a variety of serious conditions such as Parkinson's, multiple sclerosis and cerebral palsy. From the letter, it does not appear that FDA cited the centers for performing stem cell procedures in the context of joint conditions.

Under federal regulations, adipose tissue and SVF constitute a "human cell, tissue, or cellular and tissue based product" ("HCT/P"). HCT/Ps may be regulated in one of two ways under the Public Health Service ("PHS") Act and enabling regulations. The product may be subject to Section 351 of the PHS Act, in which case it must undergo the extensive premarket approval process of a Biological License Application ("BLA"). However, the product may be subject to certain exceptions, in which case it is regulated under Section 361 of the PHS Act, which exempts it from the BLA premarket approval process. Exceptions exist for (i) "minimal manipulation" of the HCT/Ps, (ii) putting the HCT/Ps to "homologous use" and (iii) harvesting and implantation of autologous HCT/Ps during the "same surgical procedure." FDA has issued three guidances in recent years discussing how these exceptions might or might not apply in specific contexts. But as a practical matter, FDA appeared to be exercising a relatively high degree of enforcement discretion, for the most part pursuing only the more egregious cases.

Based on this recent Warning Letter, it appears FDA may be changing its approach. In the Warning Letter, FDA states that its enforcement action is based on its finding that at least two of the exceptions to Section 351 regulation do not apply. FDA first concludes that the adipose tissue is more than "minimally manipulated" in the procedure at issue because the "processing alters the original relevant characteristics relating to the tissue's utility for reconstruction, repair, or replacement." FDA further concludes that the procedure is not putting the adipose tissue to "homologous use" because the SVF "is not intended to perform the basic function or functions of adipose tissue, which generally is to cover, connect, or cushion."

As noted above, there is a third exception to Section 351 regulation for HCT/Ps that are removed and transplanted back into the same patient during a single surgical procedure. In its guidance, FDA has stated its intention to apply this exception where the HCT/Ps are not subjected to "intervening steps beyond rinsing cleansing, or sizing, or certain manufacturing steps." FDA's stated reasoning is that such limited procedures "raise no additional risks of contamination and communicable disease transmission beyond that typically associated with surgery."1 Based on the Warning Letter's description of IV or intrathecal injection and nasal or oral nebulization, it appears that the cited procedures may not involve harvesting and implantation in the same procedure, in which case this exception would be inapplicable. FDA also cites CGMP and CGTP violations relating to such issues as contamination, record-keeping, and labeling, which also may have been a factor in FDA's approach in this case.

Many practitioners and organizations currently practice various forms of stem cell therapies using SVF derived from adipose tissue. As noted above, one of the most common uses of this procedures is in orthopedic and rehabilitation medicine for surgical or arthritic joints. To date, there appear to be few if any peer-reviewed, evidence-based studies reporting the success of this procedure to statistical significance. As a practical matter, payers are continuing to decline coverage on the ground that the procedure is experimental. However, anecdotal reports of success using this procedure are commonplace.

On balance, while this recent Warning Letter raises the possibility that FDA may be taking a more aggressive enforcement approach with regard to stem cell therapy, questions still remain regarding how far FDA will undertake enforcement activity in this area in particular circumstances, not least of which is in the popular orthopedic/rehabilitation field.

An interesting trend, which has continued in this Warning Letter, is the use of CGMP violations and other process violations as grounds for action. In many cases, these determinations have been made in the context of the issuance of letters to manufacturers of products about which FDA is known to be skeptical.

In a broader context, this development is of a piece with a number of recent policy reversals by FDA toward more restrictive regulation in a variety of innovative therapeutic initiatives. There is speculation that the agency is attempting to conclude rulemaking in a number of topics in anticipation both of a potential change in party and enactment by Congress of the 21st Century Cures Act. The former could affect regulatory priorities and approaches. The latter, if it proceeds on its present path, would profoundly affect both the type of data FDA will have to consider when evaluating such therapies, and in many cases change the outcome of FDA's evaluation of therapies.

In the near term, it seems clear that if FDA does proceed to increase enforcement in this area, which is of great interest to both practitioners and patients, it is almost certain that there will be a vigorous response from the various stakeholders.

Footnote

1. FDA, Same Surgical Procedure Exception Under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception, at 3 (Draft Guidance for Industry October 2014).


Learn more about our Life Sciences practices.

Orignally published January 20, 2016

Visit us at mayerbrown.com

Mayer Brown is a global legal services provider comprising legal practices that are separate entities (the "Mayer Brown Practices"). The Mayer Brown Practices are: Mayer Brown LLP and Mayer Brown Europe – Brussels LLP, both limited liability partnerships established in Illinois USA; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales (authorized and regulated by the Solicitors Regulation Authority and registered in England and Wales number OC 303359); Mayer Brown, a SELAS established in France; Mayer Brown JSM, a Hong Kong partnership and its associated entities in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. "Mayer Brown" and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.

© Copyright 2016. The Mayer Brown Practices. All rights reserved.

This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions